Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials

Basit Öğe Kaydı
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorSeber, Selcuk
dc.contributor.authorBasaran, Gul
dc.date.accessioned2024-10-29T17:43:27Z
dc.date.available2024-10-29T17:43:27Z
dc.date.issued2016
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractLate and recurrent stage ovarian cancer has a high mortality and low response rate to therapy beyond first line treatment. Although first line platinum/taxane based regimens have a satisfactory response rate eventually in most cases disease recurrence is common and second-line treatments are not curative. Delaying progression or recurrence is the main goal of current ongoing clinical studies by means of establishing an effective maintenance regimen with acceptable toxicity profile. Clearly, the persistence of dormant and drug-resistant cells after front-line treatments results in the inability to cure the disease. Over the past several years, the idea of prolongation of therapy for ovarian cancer has garnered clinical attention and academic debate. As a result of a greater understanding of the molecular pathways involved in carcinogenesis and tumor growth, a large number of potential therapeutic targets have been identified and drugs to block receptors, ligands or pathways are being developed. Currently, numerous clinical trials with targeted agents have just been completed or are ongoing involving patients achieving a complete or durable response after first-line and beyond the first line chemotherapy in order to evaluate the efficacy of different therapeutic approaches in terms of progression-free survival and overall survival. © 2015 Elsevier Ireland Ltd.
dc.identifier.doi10.1016/j.critrevonc.2015.10.006
dc.identifier.endpage188
dc.identifier.issn1040-8428
dc.identifier.pmid26603345
dc.identifier.scopus2-s2.0-84957442410
dc.identifier.scopusqualityQ1
dc.identifier.startpage180
dc.identifier.urihttps://doi.org/10.1016/j.critrevonc.2015.10.006
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12387
dc.identifier.volume98
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Ireland Ltd
dc.relation.ispartofCritical Reviews in Oncology/Hematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMaintenance treatment
dc.subjectOvarian cancer
dc.subjectTargeted therapy
dc.titleReview of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials
dc.typeReview Article

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu